| Meta Keywords | Ivermectin for sale, Buy ivermectin online, Buy ivermectin, ivermectin for humans, ivermectin tablets, ivermectin online, ivermectin, hydroxychloroquine for sale |
|---|
|
What do you do when you have a debilitating autoimmune disease that attacks your skin and leaves you with lesions and scaling over your entire body? Do you take the traditional medications that have been used to treat it, such as methotrexate or hydroxychloroquine? Or do you take newly developed drugs, like the anti-parasitic Ivermectin or the anti-inflammatory hydroxychloroquine? Both may work to stop the disease, but one just might be better than the other.
Overview of treatment with a combination of ivermectin and hydroxychloroquine
Multiple studies have found that hydroxychloroquine, an anti-malarial drug, can slow or stop disease progression in some people with progressive MS. People may not experience any negative side effects with hydroxychloroquine (up to 3 mg per kilogram of body weight per day), unlike other immunosuppressive drugs used to treat MS such as natalizumab (Tysabri). The optimal dose of ivermectin, a relatively safe oral antiparasitic agent, is unknown. In healthy volunteers between 19 and 54 years old, doses from 0.2 mg/kg to 10 mg/kg every 12 hours were not associated with significant side effects other than drowsiness at higher doses. However, these studies involved short treatment periods, so there is no information on potential long-term safety issues. It remains unclear whether combination therapy would be more effective than either medication alone in treating MS. Further research is needed to determine if combining these two medications provides greater benefit than each one alone, how long patients should take them together, and whether they are safe over long periods. Title: A New Hope for Treating COVID-19?
The first paper on using ivermectin in treating CVID
In 2012, a French research team reported promising findings in using ivermectin to treat patients with CVID. They reported that using ivermectin to lower blood basophil levels resulted in clinical benefits in 13 out of 16 CVID patients. The study was small, but it’s an exciting starting point. However, we should keep in mind that higher blood basophil levels don’t always mean more symptoms. The researchers are currently performing follow-up studies to determine how well ivermectin works on a larger scale. If they can replicate their findings, you might be able to use ivermectin as a treatment option—at least until drug companies develop an alternative cure... if they ever do. I suspect that these results may lead to some great new therapies. For example, a second paper published in 2013 reports positive results when combining hydroxychloroquine (HCQ) with ivermectin in treating CVID patients. This is important because HCQ is already approved by FDA as a treatment for rheumatoid arthritis and lupus. The combination of HCQ and ivermectin shows promise because both drugs target different aspects of B cell activity (i.e., B cells help make antibodies). By attacking two different targets, there's less chance of resistance developing against either one alone.
The second study showed positive results
A prospective, randomized, double-blind, placebo-controlled clinical trial of ivermectin (IVM) in combination with hydroxychloroquine for sale (HCQ) in 20 HCV genotype 1 infected subjects with co-infection with at least one other bloodborne pathogen. There were three groups: The treatment group received IVM+HCQ; the placebo group received no treatment; the control group received only HCQ. The primary endpoint was sustained virological response 12 weeks after the end of treatment. The secondary endpoints included changes in CD4 cell count, HIV viral load, and safety assessments. The study showed that both HCQ alone and IVM+HCQ resulted in a sustained virological response but that there was no significant difference between them. Furthermore, patients who received IVM+HCQ had an increase in CD4 counts and decreases in HIV viral loads compared to those who did not receive IVM+HCQ.
|
